Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP protection, and patient tolerability, writes Enveric Biosciences CEO Joseph ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver products that improve upon currently available treatments for obesity.

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without risking exclusive rights over valuable assets, writes Richard Gold.

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesnt have to be that way, writes Anastasia Christianson, Ph.D.

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate risk, and comply with emerging AI regulations.

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin testing. Charles River Labs Nicola Reid lays out the issues to consider.

AC Immune SA cofounder and CEO Andrea Pfeifer offers lessons in strategy and resilience for building and maintaining a drug development company amid internal and external ups and downs.

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.